Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
May 08, 2024 09:00 ET
|
Therini Bio, Inc.
THN391, a mAb designed to block neuroinflammation triggered by fibrin, demonstrated effectiveness in protecting against vascular and neuronal degeneration
Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia
October 24, 2023 09:05 ET
|
Therini Bio, Inc.
- THN391 was found to be safe and well-tolerated -- THN391 demonstrated a prolonged half-life and dose proportional Cmax levels -- The data will be presented October 25-27th at CTAD 2023 - ...